An update on advanced glycation endproducts and atherosclerosis

Monocyte-endothelium-smooth muscle cell interaction in co-culture: Proliferation and cytokine productions in response to advanced glycation end products

(2011) Mi-Hyun Nam et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Advanced Glycation End Products, Measured as Skin Autofluorescence and Diabetes Complications: A Systematic Review

(2011) Dieuwke C. Bos et al.   Diabetes Technology & Therapeutics

Naturally occurring inhibitors against the formation of advanced glycation end-products

(2011) Xiaofang Peng et al.   Food & Function

Aldose Reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats

(2010) Kellie McCormick Hallam et al.   AGING CELL

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Oxidative Stress and Diabetic Complications

(2010) Ferdinando Giacco et al.   CIRCULATION RESEARCH

Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation

(2010) Niccolo Lanati et al.   Current Vascular Pharmacology

Advanced glycation end-products: Implications for diabetic and non-diabetic nephropathies

(2009) M. Daroux et al.   DIABETES & METABOLISM

Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study

(2009) J. W. M. Nin et al.   DIABETOLOGIA

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease

(2009) Shi Fang Yan et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts

(2009) Ravichandran Ramasamy et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Plasma Carboxymethyl-Lysine, an Advanced Glycation End Product, and All-Cause and Cardiovascular Disease Mortality in Older Community-Dwelling Adults

(2009) Richard D. Semba et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Serum Carboxymethyl-Lysine, an Advanced Glycation End Product, Is Associated With Increased Aortic Pulse Wave Velocity in Adults

(2008) R. D. Semba et al.   AMERICAN JOURNAL OF HYPERTENSION

Advanced Glycation End-Product of Low Density Lipoprotein Activates the Toll-Like 4 Receptor Pathway Implications for Diabetic Atherosclerosis

(2008) Conrad P. Hodgkinson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis

(2008) Kikuo Isoda et al.   ATHEROSCLEROSIS

Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes

(2008) Naoto Katakami et al.   ATHEROSCLEROSIS

Oxygen Deprivation Triggers Upregulation of Early Growth Response-1 by the Receptor for Advanced Glycation End Products

(2008) Jong Sun Chang et al.   CIRCULATION RESEARCH

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes

(2008) A. Soro-Paavonen et al.   DIABETES

A Perspective on the Maillard Reaction and the Analysis of Protein Glycation by Mass Spectrometry: Probing the Pathogenesis of Chronic Disease

(2008) Qibin Zhang et al.   JOURNAL OF PROTEOME RESEARCH

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Disease: advanced glycation end-products and their receptor in inflammation and diabetes complications

(2008) Shi Fang Yan et al.   Nature clinical practice. Endocrinology & metabolism

Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications

(2007) Giuseppina Basta   ATHEROSCLEROSIS